Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Kamoya Leaves Chuikyo as Industry Rep, Lauds Breakthrough for Essential Drug Rule
October 30, 2017
- Opdivo Could Face Deeper Cut with Revision of Dosage-Change Re-Pricing Rule; Keytruda Could Be Affected Too
October 30, 2017
- CEFP Kicks Off FY2018 Budget Debate with Major Focus on Scope of Off-Year Price Survey, Revision
October 27, 2017
- MHLW Issues Notification Revising GPSP Ordinance in Response to Medical Information Database
October 27, 2017
- Scrap Price Maintenance Premium, or Limit Scope of Products: MOF
October 26, 2017
- Chuikyo Proposes 5% ICER Deduction for Each Ethical/Societal Criteria Met
October 26, 2017
- Chuikyo OKs “5 Million Yen,” “10 Million Yen” Thresholds for 3-Segment CEA Price Adjustment Model
October 26, 2017
- Payer Rep Insists CEA-Based Price Hike “Not an Option,” MHLW Wants “Grounds” for That Argument: Chuikyo
October 26, 2017
- Consumer Representative on MHLW Advisory Panel Resigns after Taking Regular Payments from Megmilk Snow Brand
October 26, 2017
- Patient Dies due to Mix-Up of Lixiana, Rifxima; PMDA, Companies Issue Warning Statement
October 26, 2017
- Cabinet Approves 5-Year Plan to Promote Anticancer Measures
October 26, 2017
- Sanofi’s Dupilumab, Chugai’s PD-L1 Inhibitor and More Up for MHLW Panel Review on Nov. 6
October 25, 2017
- Conditional Early Approval System Gets Underway: MHLW
October 23, 2017
- LDP Healthcare Big Names Handily Nab Seats in Snap Election
October 23, 2017
- MHLW to Discuss Drug Wholesalers’ License Requirements Related to Their “Operational Systems”
October 23, 2017
- MHLW to Discuss Redefinition of Drug “Seals”, Will Revise List of Examples of Seals Included in 1961 Notification
October 23, 2017
- Japan Introduction of GDP Likely to Begin with Guideline that Calls on Companies to Make “Good Faith Effort”: MHLW Study Group
October 23, 2017
- MHLW Advisory Panel to Discuss Pediatric Dosages for Nexium on Nov. 2
October 20, 2017
- Restrictions on Continuous Psychotropic Use Up for Chuikyo Discussions
October 19, 2017
- Price Maintenance Premium, Z2 Reduction Rates under Attack by CEFP Working Group
October 19, 2017
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…